IPO registrations (S-1, F-1) · Registrants
Ocugen, Inc.
- SEC CIK
- 1372299 · filings on EDGAR ↗
- Name on the registration
- HISTOGENICS CORP
- Former names
- HISTOGENICS CORP (2006–2019)
- Registration
- Form S-1, first filed 2014-10-07, last 2014-12-02; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2014-12-03; declared effective 2014-12-02
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 11 GREAT VALLEY PARKWAY, Malvern, PA 19355
- Ticker
- OCGN (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Ocugen, Inc. on the corporate pages
Offering terms
- Final price
- $11.00 per share (424B4 filed 2014-12-03, an initial public offering)
- Shares sold
- 5,909,091
- Gross proceeds
- $65,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol HSGX
- Lead underwriters
- Cowen
- Syndicate
- Needham & Company; Canaccord Genuity; BTIG
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Ocugen, Inc. Fuzzy (name and state)
- Form D issuer: Ocugen, Inc. EXACT (CIK (EXACT))
- Lobbying client: OCUGEN INC Fuzzy (name and state)
- Lobbying client: OCUGEN INC. Fuzzy (name and state)
- Lobbying client: OCUGEN, INC. Fuzzy (name and state)
- Lobbying client: OCUGEN, INC. Fuzzy (name and state)
- SEC filer: HISTOGENICS CORP EXACT (CIK (EXACT))
- Person page: David C Hood Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2014-10-07 | S-1 | S-1 (registration) | HISTOGENICS CORP | 0001193125-14-365761 ↗ |
| 2014-11-07 | S-1/A | S-1/A (amendment) | HISTOGENICS CORP | 0001193125-14-403509 ↗ |
| 2014-11-14 | S-1/A | S-1/A (amendment) | HISTOGENICS CORP | 0001193125-14-413126 ↗ |
| 2014-11-26 | S-1/A | S-1/A (amendment) | HISTOGENICS CORP | 0001193125-14-427246 ↗ |
| 2014-12-02 | S-1/A | S-1/A (amendment) | HISTOGENICS CORP | 0001193125-14-430664 ↗ |
| 2014-12-02 | EFFECT | EFFECT (declared effective) | HISTOGENICS CORP | 9999999995-14-003555 ↗ |
| 2014-12-03 | 424B4 | 424B4 (final prospectus) | HISTOGENICS CORP | 0001193125-14-432202 ↗ |
| 2016-11-04 | EFFECT | EFFECT (declared effective) | HISTOGENICS CORP | 9999999995-16-006154 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-12-02 | S-1/A | registration statement | $0.01 | 5,654 | $56 | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ | ||
| 2014-12-03 | 424B4 | final prospectus | $11.00 | 5,909,091 | $65,000,000 | Nasdaq HSGX | 4 | primary document; price sentence, shares headline, proceeds table, cover names 4 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| AKKARAJU SRINIVAS | TenPercentOwner | 2 | 2014 | ||
| Baltzell Joshua J | Director | 5 | 2014–2018 | ||
| Gridley Adam | Director,Officer | President and CEO; See Remarks | 8 | 2014–2018 | |
| HEALY JAMES | TenPercentOwner | 2 | 2014 | ||
| JOHNSON JOHN | Director | 5 | 2014–2018 | ||
| Kennedy Stephen Richard | Officer | Chief Operating Officer; Chief Technology Officer; EVP and COO; Senior VP of Operations; SVP of Technical Operations | 8 | 2014–2018 | |
| Kong Garheng | Director | 5 | 2014–2018 | ||
| Lewis Michael | Director; Director,TenPercentOwner | 11 | 2014–2019 | ||
| Lynch Nancy | Officer | Chief Medical Officer | 1 | 2014 | |
| McArdle Kevin | Officer | Chief Financial Officer | 2 | 2014–2015 | |
| Mehra Anand | TenPercentOwner | 2 | 2014 | ||
| POWELL MICHAEL | TenPercentOwner | 2 | 2014 | ||
| RAKIN KEVIN | Director | 10 | 2014–2019 | ||
| Sofinnova Management VIII, L.L.C. | TenPercentOwner | 2 | 2014 | ||
| Sofinnova Venture Partners VIII, L.P. | TenPercentOwner | 2 | 2014 | ||
| SPLIT ROCK PARTNERS II, LP | TenPercentOwner | 4 | 2014–2017 | ||
| SPLIT ROCK PARTNERS II MANAGEMENT, LLC | TenPercentOwner | 4 | 2014–2017 | ||
| Wilmslow Estates Ltd | TenPercentOwner | 7 | 2014–2019 | ||
| INTREXON CORP | TenPercentOwner | 2 | 2014–2019 | ||
| KIRK RANDAL J | TenPercentOwner | 2 | 2014–2019 | ||
| GILL DAVID N | Director | 10 | 2015–2018 | ||
| Lieber Jonathan I | Officer | Chief Financial Officer | 7 | 2015–2018 | |
| Matthews Gloria | Officer | Chief Medical Officer | 4 | 2015–2017 | |
| Haut Donald | Officer | Chief Business Officer | 4 | 2017–2018 | |
| Washer Susan B. | Director | 2 | 2018 | ||
| Kelley Lynne E | Officer | Chief Medical Officer | 3 | 2018 | |
| Hood David C. | Director | 1 | 2019 | person page Fuzzy | |
| Subramanian Sanjay | Officer | Chief Financial Officer | 17 | 2019–2022 | |
| Zhang Junge | Director | 23 | 2019–2026 | ||
| Musunuri Shankar | Director,Officer | Chief Executive Officer | 27 | 2019–2026 | |
| Arumugham Rasappa | Officer | Chief Scientific Officer | 3 | 2019–2020 | |
| Beck Kelly | Officer | Vice President | 3 | 2019–2020 | |
| JORGENSEN DANIEL | Officer | Chief Medical Officer | 3 | 2019–2020 | |
| Kompella Uday | Director | 18 | 2019–2026 | ||
| Kumar Ramesh | Director | 13 | 2019–2023 | ||
| Leo Frank | Director | 2 | 2019–2020 | ||
| Tammara Vijay | Officer | Senior Vice President; Vice President | 7 | 2019–2021 | |
| Taspolatoglu Suha | Director | 3 | 2019–2021 | ||
| Potti Manish | Director | 8 | 2019–2021 | ||
| Castillo Kirsten | Director | 14 | 2020–2026 | ||
| Fernandes Prabhavathi | Director | 9 | 2020–2024 | ||
| Crespo Jessica | Officer | CAO/SVP, Finance | 4 | 2022–2023 | |
| WHITTINGTON MARNA C | Director | 5 | 2022–2024 | ||
| Upadhyay Arun | Officer | Chief Scientific Officer; See Remarks | 10 | 2023–2025 | |
| Vu Quan Anh | Officer | CFO/CBO | 1 | 2023 | |
| Breininger Michael | Officer | See Remarks | 1 | 2024 | |
| Qamar Huma | Officer | Chief Medical Officer | 3 | 2024–2025 | |
| Ramachandran Ramesh | Officer | Chief Accounting Officer | 3 | 2024–2026 | |
| Chandrasekhar Satishchandran | Director | 4 | 2025–2026 | ||
| Coleman Blaise | Director | 3 | 2025–2026 | ||
| Johnson-Greene Treerita Essalima | Officer | Chief Financial Officer | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2020-05-07 | Ocugen, Inc. | Biotechnology | $395 | $395 | 1 | 1 |
| 2020-05-07 | Ocugen, Inc. | Biotechnology | $14,283,724 | $14,283,724 | 6 | 1 |
| 2016-10-12 | HISTOGENICS CORP | Other Health Care | $30,000,001 | $30,000,001 | 20 | 1 |
| 2014-01-06 | HISTOGENICS CORP | Other Health Care | $20,647,968 | $10,323,988 | 17 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Form D issuer | Ocugen, Inc. | PA | Form D private offerings | CIK (EXACT) |
| SEC filer | Ocugen, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | Ocugen, Inc. | State business registries | name and state | |
| Lobbying client | OCUGEN INC | Federal lobbying (LDA) | name and state | |
| Lobbying client | OCUGEN INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | OCUGEN, INC. | Federal lobbying (LDA) | name and state | |
| Lobbying client | OCUGEN, INC. | Federal lobbying (LDA) | name and state | |
| Person page | David C Hood | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), PA first:
- APOLLON INC PA
- Aevi Genomic Medicine, LLC PA
- Spark Therapeutics, Inc. PA
- Krystal Biotech, Inc. PA
- Cabaletta Bio, Inc. PA
- Passage BIO, Inc. PA
- Century Therapeutics, Inc. PA
- Aphton CORP PA
- Aceragen, Inc. PA
- GENAERA CORP PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health